Skip to content

The effect of alpha ointment in treatment of burned patients

Comparison between effect of Alpha and Silver Sulfadiazine ointments in treatment of burned patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015110624905N1
Enrollment
40
Registered
2016-02-09
Start date
2014-09-27
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burning. Contact with hot drinks, food, fats and cooking oils

Interventions

Intervention 1: Patients in the burning ward, was treated accidentally with Alpha ointment which made in Rejoderm company and Silver Sulfadiazine ointment which made in Sina Darou company. In this stu
Treatment - Drugs
Patients in the burning ward, was treated accidentally with Alpha ointment which made in Rejoderm company and Silver Sulfadiazine ointment which made in Sina Darou company. In this study we choose pat
Because this study was done over patients with two burned limbs, in all patients one limb accidentally was dressed with Alpha ointment and the other limb was dressed with Silver Sulfadiazine ointment.

Sponsors

Zanjan University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Second degree heat burned patients; burning surface area between 10% and 20% Exclusion criteria:Iisolated head and neck burning; burning of genitalia; pregnant women; first and third and fourth degree burning; unstable patients; burning surface area above 20% or under 10%; patients with history of neurocycotic diseases who are under treatment; addiction to opioids; smokers; patients with history of cardiac, renal or hepatic diseases; diabetic patients; malnutrished patients; patients under treatment of corticosteroids or other immune suppressive treatments; inhalative burnings; sulfunamid toxicity; old burnings

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Rate of ulcer healing. Timepoint: Seventh, 14th, 30th day. Method of measurement: Evaluation of patient in the admission time and evaluation of ulcers in 7th and 14th day of admission and out patient in day 30th. In every visit photography of ulcers was done.;The rate of scar. Timepoint: Thirtieth day. Method of measurement: Two other colleagues who were not aware of our protocol, visited patients in 30th day and scored rate of scar in 4 qualitative scale item like excellent, good, intermediate, poor. And the remaining scar was reported in percentage.;The rate of positive culture. Timepoint: First, 7th, 14th day. Method of measurement: The cuture of wound swap in the first, 7th and 14th day of admission.

Secondary

MeasureTime frame
The rate of patients' pain. Timepoint: Daily. Method of measurement: VAS (visual analogue scale) in first 14 day.;Dose of recieved analgesia. Timepoint: Daily. Method of measurement: Evaluation of pethidine consumption in firs 14 day.;Days of admission. Timepoint: Daily. Method of measurement: Questionnarie.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPayman Sadri

Zanjan University of Medical Science

Sadrip@zums.ac.ir; Payman169@yahoo.com+98 24 3310 0001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026